FDA oversight of drug company promotion of off-label use is poor, US watchdog saysBMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a1163 (Published 05 August 2008) Cite this as: BMJ 2008;337:a1163
- Janice Hopkins Tanne
- 1New York
The US Food and Drug Administration does a poor job of monitoring drug companies’ promotion of unapproved or “off-label” uses of their drugs, says a report by the US Government Accountability Office, the investigative arm of Congress.
Charles Grassley, an Iowa senator who is the senior Republican member of the Senate Committee on Finance, asked the accountability office to review the FDA’s effectiveness in monitoring drug companies’ efforts to promote off-label uses. He said he was concerned about the possible effects of such promotion on doctors’ prescribing practices and on patients’ safety.
Although doctors may prescribe drugs off label for indications that have not been approved by the FDA, drug companies are forbidden from promoting such unapproved uses.
The accountability office’s report said the FDA’s …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial